Search Results: Treatment + Breast Cancer (24 results)

Evaluate the Benefit of Adding ART6043 to Olaparib for HER2-Negative Metastatic or Advanced Breast Cancer and a gBRCA Mutation (POLKA)

https://www.facingourrisk.org/research-clinical-trials/study/430 /evaluate-the-benefit-of-adding-art6043-to-olaparib-for-her2-negative-metastatic-or-advanced-breast-cancer-and-a-gbrca-mutation-polka

Treatment
Metastatic breast cancer treatment study

This study is evaluating the addition of ART6043, a novel targeted therapy, to olaparib, a standard treatment, in adults with HER2-negative advanced or metastatic breast cancer and an inherited germline BRCA mutation.

ERADICATE: Hormone and Targeted Therapy for HR+/HER2-Low Advanced Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/447 /eradicate-hormone-and-targeted-therapy-for-hrher2-low-advanced-breast-cancer

Treatment
Study of hormone and targeted therapy for advanced breast cancer

The study is for people with hormone receptor-positive (HR+), HER2-low or HER2-ultralow breast cancer that has spread to other parts of the body (metastatic) or is locally advanced and cannot be removed with surgery.

Using a Computer Model to Identify Treatment Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

https://www.facingourrisk.org/research-clinical-trials/study/438 /using-a-computer-model-to-identify-treatment-options-in-advanced-metastatic-breast-cancer-synthesis-breast

Treatment
Treatment study for people with metastatic breast cancer

Researchers want to know if a computer program can help choose FDA-approved drugs that will treat advanced breast cancer more effectively.

A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advanced or Metastatic Breast Cancer who Progressed After a Prior Line of Treatment

https://www.facingourrisk.org/research-clinical-trials/study/414 /a-study-to-learn-about-the-study-medicine-called-pf-07248144-in-combination-with-fulvestrant-in-people-with-hr-positive-her2-negative-advanced-or-metastatic-breast-cancer-who-progressed-after-a-prior-line-of-treatment

Treatment
Study for adults with advanced/metastatic HR-positive, HER2-negative breast cancer who have progressed from prior treatment

This study is for adults with advanced/metastatic HR-positive, HER2-negative advanced or metastatic breast cancer who have previously been treated with a CDK4/6 inhibitor and have received two or less treatments for their advanced metastatic breast cancer.

Testing the Drug CX-5461 for Treating Metastatic Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/431 /testing-the-drug-cx-5461-for-treating-metastatic-solid-tumors

Treatment
Phase 1 study for treatment of advanced solid tumors

This early-phase study is looking at the safety, side effects, and best dose of the medication pidnarulex for treating advanced or metastatic cancers. Pidnarulex blocks a certain protein called Pol 1 that cells need to repair DNA damage.

Testing a New Targeted Therapy ETX-19477 to Treat Advanced Breast, Colorectal Endometrial, Ovarian or Pancreatic Cancer in People with a BRCA2 Mutation (ERADIC8)

https://www.facingourrisk.org/research-clinical-trials/study/432 /testing-a-new-targeted-therapy-etx-19477-to-treat-advanced-solid-tumors-eradic8

Treatment
Treatment study for people with advanced breast, colorectal, endometrial, ovarian or pancreatic cancer

Researchers are studying whether the targeted therapy ETX-19477 is a safe and effective treatment option for people with metastatic or advanced solid tumors. ETX-19477 is a type of drug known as a PARG inhibitor. It works by interfering with cancer cells' ability to repair damage to their DNA. Researchers hope this may slow tumor growth or cause cancer cells to die.The goal of this study is to find the safest and most effective dose of ETX-19477 for treating metastatic or advanced cancers. The study is currently enrolling people with a BRCA1 or BRCA2 mutation.

Study of a New Drug, Sacituzumab Tirumotecan, Given Alone or in Combination with an Immunotherapy for Metastatic, Triple-Negative Breast Cancer (TroFuse-011)

https://www.facingourrisk.org/research-clinical-trials/study/359 /study-of-a-new-drug-sacituzumab-tirumotecan-given-alone-or-in-combination-with-an-immunotherapy-for-people-with-triple-negative-breast-cancer

Treatment
Phase 3 treatment study for people with metastatic, triple-negative breast cancer

This study is testing a new targeted therapy, sacituzumab tirumotecan, given alone or with the immunotherapy Keytruda (pembrolizumab) to treat metastatic, triple-negative breast cancer (TNBC). Keytruda is an immunotherapy that is FDA approved to treat TNBC. The goal of the study is to learn how well sacituzumab tirumotecan can cause tumors to shrink or disappear and how long that response lasts.

Comparing Hormone Therapy With and Without Chemotherapy for Premenopausal Breast Cancer (OFSET)

https://www.facingourrisk.org/research-clinical-trials/study/388 /comparing-hormone-therapy-with-and-without-chemotherapy-for-premenopausal-breast-cancer-ofset

Treatment
Study for premenopausal, early-stage, ER positive, HER2-negative breast cancer

This phase 3 study is for premenopausal people with early-stage ER-positive/HER2-negative breast cancer. The study is testing whether adding chemotherapy after surgery to standard ovarian function suppression and endocrine (hormone) therapy can help prevent breast cancer from coming back in younger women with early-stage disease.

Treating Advanced Breast Cancer or Other Solid Cancers Using a Combination of a New Targeted Therapy, ZEN003694, With The Targeted Therapy Abemaciclib (Verzenio)

https://www.facingourrisk.org/research-clinical-trials/study/363 /testing-a-new-drug-zen003694-with-chemotherapy-abemaciclib-for-people-with-advanced-or-inoperable-breast-cancer-and-other-solid-tumors

Treatment
Phase 1 treatment study for advanced breast cancer and other solid tumors

This clinical trial is studying whether the combination of two targeted therapies, abemaciclib (Verzenio) and a new targeted therapy ZEN003694 (also known as ZEN-3694) can be given together safely and what dose should be used in future studies.

Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/300 /study-of-a-new-investigationai-inhibitor-to-treat-people-with-advanced-solid-tumors

Treatment
Treatment study for people with advanced solid tumors

The study will test if an investigational treatment, XL309, is safe and works when used alone or in combination with a PARP inhibitor to treat people with some advanced solid tumors. The study is enrolling people with BRCA1 or BRCA2 inherited mutations and have HER2-negative breast cancer, prostate cancer, pancreatic cancer, high grade ovarian, fallopian tube or primary peritoneal cancer; or other solid tumors with certain genetic mutations.

A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with an ATM, BRCA1/2, CHEK2, PALB2 or Other Mutation

https://www.facingourrisk.org/research-clinical-trials/study/377 /an-new-targeted-therapy-cx5461-to-treat-advanced-breast-ovarian-pancreatic-or-prostate-cancer-with-inherited-or-tumor-mutations

Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer

This research study is testing the safety and effectiveness of an investigational targeted therapy called CX‑5461. The goal is to find a safe dose and learn more about how well the drug works to treat advanced breast, ovarian, pancreatic or prostate cancers in people with certain inherited or tumor‑related gene mutations, including ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, NBN, PALB2, RAD51C, RAD51D or other mutations related to DNA repair.

Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)

https://www.facingourrisk.org/research-clinical-trials/study/349 /studying-a-new-parp-inhibitor-and-hormonal-therapy-to-treat-her2-negative-hr-positive-metastatic-breast-cancer-with-a-brca1-brca2-or-palb2-mutation-evopar-br01

Treatment
Phase 3 treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation

EvoPAR-BR01 is studying two investigational drugs as first-line treatment for HER2-negative, HR-positive, metastatic breast cancer in people with an inherited or tumor mutation in BRCA1, BRCA2 or PALB2. Saruparib is a new PARP1 inhibitor (a type of targeted therapy). Camizestrant is an estrogen receptor degrader (a type of hormonal therapy). The study will look at different combinations of treatments to learn which combination leads to the best survival and fewest side effects.

Treating Advanced or Metastatic Cancers with a New PARP1 Inhibitor (GS-0201) Alone or Combined with Other Drugs

https://www.facingourrisk.org/research-clinical-trials/study/350 /treating-advanced-or-metastatic-cancers-with-the-new-parp-inhibitor-alone-or-combined-with-other-drugs

Treatment
Treatment study for people with advanced or metastatic solid tumors

The goal of this treatment study is to learn if the new drug GS-0201 is safe and can help treat people with different types of metastatic or advanced cancer. GS-0201 is a new drug that has not yet been approved for treatment of cancer. GS-0201 is a type of targeted therapy known as a PARP1 inhibitor.

Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug, Axatilimab, Combined with Olaparib

https://www.facingourrisk.org/research-clinical-trials/study/345 /treating-her2-negative-brca12-or-palb2-positive-metastatic-breast-cancer-using-a-new-drug-combined-with-olaparib

Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation

This clinical trial is studying a new combination of drugs to treat metastatic, HER2-negative or HER2-low breast cancer in people with an inherited mutation in BRCA1, BRCA2 or PALB2 or a tumor mutation in BRCA1 or BRCA2. The study is looking at whether adding a new targeted therapy drug called axatilimab to treatment with the PARP inhibitor olaparib (Lynparza) will improve outcomes in people with metastatic breast cancer.

Looking at Tumor DNA Before Chemotherapy to Predict Cancer Recurrence in People with High-Risk, Early-Stage Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/344 /study-looking-at-tumor-dna-to-predict-cancer-recurrence-for-those-planning-to-undergo-chemotherapy-for-high-risk-early-breast-cancer

Treatment
Biomarker study for people with early-stage breast cancer

This is a study looking at biomarkers to predict recurrence in people with high-risk, early-stage breast cancer who are planning to undergo chemotherapy. This study will follow patients forward over a period of time to see how well the test cancer predict outcomes.

Testing a Shorter Course of Chemo- and Immunotherapy (Without Anthracycline Drugs) for People With Early-Stage Triple-Negative Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/343 /a-study-testing-shorter-safer-chemo-immunotherapy-without-anthracycline-drugs-for-people-with-early-stage-triple-negative-breast-cancer

Treatment
Treatment study for early-stage triple-negative breast cancer

This study is testing whether a shorter course of combined chemotherapy and immunotherapy treatment—without a type of chemotherapy known as an anthracycline—works as well as the standard, longer treatment for people with early-stage triple-negative breast cancer at high risk for recurrence.

Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/304 /olaparib-with-cediranib-or-ceralasertib-for-people-with-advanced-or-metastatic-breast-cancer-and-with-a-brca1-or-brca2-mutation

Treatment
Treatment study for people with advanced breast cancer who have a BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor

This study is for people with advanced or metastatic breast cancer, have a BRCA1 or BRCA2 genetic mutation and were previously treated with a PARP inhibitor. The study will examine how effective Olaparib in combination with Cediranib or Ceralasertib is in reducing the size of cancer and determining the length of time patients respond well to the treatment.

Study of a New Treatment Called ONM-501 Alone and in Combination with Immunotherapy for Triple Negative Breast Cancer, Advanced Solid Tumors and Lymphomas

https://www.facingourrisk.org/research-clinical-trials/study/311 /study-of-a-new-treatment-called-onm-501-alone-and-in-combination-with-cemiplimab-in-people-with-triple-negative-breast-cancer-advanced-solid-tumors-and-lymphomas

Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas

This study is looking at the safety and best dose for treatment with the drug ONM-501 alone or in combination with immunotherapy for treating advanced solid tumors or lymphomas.

Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)

https://www.facingourrisk.org/research-clinical-trials/study/282 /study-of-the-parp-inhibitor-azd9574-alone-and-combined-with-other-cancer-medicines-to-treat-people-with-advanced-solid-cancers-certis1-study

Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas

This research involves studying a drug called AZD9574 on its own and in combination with other anti-cancer drugs in people with advanced cancer that has come back or progressed. AZD9574 is a type of targeted therapy known as a PARP inhibitor. The study aims to understand the safety, tolerance, how the drug moves in the body, how it affects the body, and its initial effectiveness.

TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer

https://www.facingourrisk.org/research-clinical-trials/study/262 /tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer

Treatment
Cancer treatment study for people with advanced solid tumors

The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.

Study of the drug TNG260 and an Immunotherapy in Advanced Solid Tumors With a STK11 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/333 /study-of-the-drug-tng260-and-an-immunotherapy-in-advanced-solid-tumors-with-a-stk11-mutation

Treatment
This is a treatment study enrolling people with advanced or metastatic solid tumors with known STK11 mutations

The study is designed to find the safest dose of a drug called TNG260, given along with a standard dose of the immunotherapy drug pembrolizumab, in people with advanced or metastatic solid tumors and have a STK11 genetic mutation.

Treating Metastatic Breast or Pancreatic Cancer in People with an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Stem Cells

https://www.facingourrisk.org/research-clinical-trials/study/117 /sharon-a-clinical-trial-for-metastatic-cancer-with-an-inherited-brca-or-palb2-mutation-using-chemotherapy-and-patients-own-stem-cells

Treatment
Treatment study for metastatic breast or pancreatic cancer in people with an inherited BRCA1 or BRCA2 mutation

The purpose of this study is to see whether the combination of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous (self) bone marrow stem cell infusion, is safe and effective for treating patients with advanced pancreatic cancer or Stage IV, HER2-negative breast cancer who have a BRCA1, BRCA2 or PALB2 inherited mutation. All of these treatments are given intravenously (by vein). This study is open to people who have already received a PARP inhibitor, as well as those who have not. There are no restrictions on the number of prior treatments a patient has received before enrolling.

Treatment with an ATR Inhibitor for Advanced or Metastatic Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/157 /treatment-with-atr-inhibitor-for-advanced-or-metastatic-solid-tumors

Treatment
Phase 1/2 treatment study for advanced solid tumors

This study will look at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes linked to DNA damage repair. The study will look at response to treatment with the drug ART0380 in combination with the chemotherapy agent, gemcitabine.

Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations

https://www.facingourrisk.org/research-clinical-trials/study/100 /talazoparib-for-people-with-metastatic-breast-cancer-who-have-acquired-somatic-brca-mutations

Treatment
Treatment study for people with metastatic breast cancer without a known mutation in BRCA1 or BRCA2, who learn they have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation)

This is a study for patients with metastatic breast cancer who do not have an inherited mutation in BRCA1 or BRCA2 but who are are found to have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation) found through liquid biopsy. Patients are treated with talazoparib, a well-tolerated oral PARP inhibitor that targets the BRCA1and BRCA2 mutation to determine whether this treatment (which is already approved for germline BRCA1 and BRCA2 carriers) is effective in this population.

Additional Results on Clinicaltrials.gov Treatment + Breast Cancer
490 results

A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT ID: NCT04389632 (https://clinicaltrials.gov/study/NCT04389632)

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
NCT ID: NCT05035836 (https://clinicaltrials.gov/study/NCT05035836)

A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
NCT ID: NCT07705334 (https://clinicaltrials.gov/study/NCT07705334)

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
NCT ID: NCT05455619 (https://clinicaltrials.gov/study/NCT05455619)

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
NCT ID: NCT06374459 (https://clinicaltrials.gov/study/NCT06374459)

Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
NCT ID: NCT06444269 (https://clinicaltrials.gov/study/NCT06444269)

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
NCT ID: NCT05111561 (https://clinicaltrials.gov/study/NCT05111561)

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT ID: NCT05579366 (https://clinicaltrials.gov/study/NCT05579366)

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
NCT ID: NCT02926690 (https://clinicaltrials.gov/study/NCT02926690)

SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases
NCT ID: NCT04923542 (https://clinicaltrials.gov/study/NCT04923542)

Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer
NCT ID: NCT06860815 (https://clinicaltrials.gov/study/NCT06860815)

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
NCT ID: NCT06799065 (https://clinicaltrials.gov/study/NCT06799065)

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NCT ID: NCT07029399 (https://clinicaltrials.gov/study/NCT07029399)

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
NCT ID: NCT06150664 (https://clinicaltrials.gov/study/NCT06150664)

Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
NCT ID: NCT01185132 (https://clinicaltrials.gov/study/NCT01185132)

Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer
NCT ID: NCT06260033 (https://clinicaltrials.gov/study/NCT06260033)

FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer
NCT ID: NCT04174352 (https://clinicaltrials.gov/study/NCT04174352)

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
NCT ID: NCT07558733 (https://clinicaltrials.gov/study/NCT07558733)

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
NCT ID: NCT07078604 (https://clinicaltrials.gov/study/NCT07078604)

Study of XB010 in Subjects With Solid Tumors
NCT ID: NCT06545331 (https://clinicaltrials.gov/study/NCT06545331)

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT ID: NCT06618287 (https://clinicaltrials.gov/study/NCT06618287)

With Love, Grandma ("Con Cariño, Abuelita") Pilot Study
NCT ID: NCT05721976 (https://clinicaltrials.gov/study/NCT05721976)

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
NCT ID: NCT07222215 (https://clinicaltrials.gov/study/NCT07222215)

Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC
NCT ID: NCT07066189 (https://clinicaltrials.gov/study/NCT07066189)

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
NCT ID: NCT06637306 (https://clinicaltrials.gov/study/NCT06637306)

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT ID: NCT05950945 (https://clinicaltrials.gov/study/NCT05950945)

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
NCT ID: NCT04895709 (https://clinicaltrials.gov/study/NCT04895709)

Palbociclib and Pembrolizumab In Central Nervous System Metastases
NCT ID: NCT02896335 (https://clinicaltrials.gov/study/NCT02896335)

Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
NCT ID: NCT05183126 (https://clinicaltrials.gov/study/NCT05183126)

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
NCT ID: NCT07454642 (https://clinicaltrials.gov/study/NCT07454642)

Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
NCT ID: NCT06353997 (https://clinicaltrials.gov/study/NCT06353997)

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
NCT ID: NCT06224673 (https://clinicaltrials.gov/study/NCT06224673)

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
NCT ID: NCT06686394 (https://clinicaltrials.gov/study/NCT06686394)

Short-Term Reduced Dietary Protein in ER+/HER2- Breast Cancer Patients During Neoadjuvant Chemotherapy
NCT ID: NCT07897344 (https://clinicaltrials.gov/study/NCT07897344)

NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
NCT ID: NCT05837455 (https://clinicaltrials.gov/study/NCT05837455)

ETHAN - ET for Male BC
NCT ID: NCT05501704 (https://clinicaltrials.gov/study/NCT05501704)

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
NCT ID: NCT06434064 (https://clinicaltrials.gov/study/NCT06434064)

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
NCT ID: NCT05020860 (https://clinicaltrials.gov/study/NCT05020860)

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
NCT ID: NCT05746897 (https://clinicaltrials.gov/study/NCT05746897)

Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
NCT ID: NCT04959474 (https://clinicaltrials.gov/study/NCT04959474)

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT ID: NCT07288359 (https://clinicaltrials.gov/study/NCT07288359)

Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer
NCT ID: NCT06910761 (https://clinicaltrials.gov/study/NCT06910761)

RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
NCT ID: NCT05256745 (https://clinicaltrials.gov/study/NCT05256745)

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
NCT ID: NCT05386108 (https://clinicaltrials.gov/study/NCT05386108)

FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy
NCT ID: NCT06917313 (https://clinicaltrials.gov/study/NCT06917313)

A Study of MT-4561 in Patients With Various Advanced Solid Tumors
NCT ID: NCT06943521 (https://clinicaltrials.gov/study/NCT06943521)

A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
NCT ID: NCT06075810 (https://clinicaltrials.gov/study/NCT06075810)

SABER Study for Selected Early Stage Breast Cancer
NCT ID: NCT04360330 (https://clinicaltrials.gov/study/NCT04360330)

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
NCT ID: NCT04348747 (https://clinicaltrials.gov/study/NCT04348747)

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT ID: NCT05879926 (https://clinicaltrials.gov/study/NCT05879926)

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
NCT ID: NCT07383506 (https://clinicaltrials.gov/study/NCT07383506)

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial
NCT ID: NCT07191717 (https://clinicaltrials.gov/study/NCT07191717)

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis
NCT ID: NCT07578116 (https://clinicaltrials.gov/study/NCT07578116)

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
NCT ID: NCT06239194 (https://clinicaltrials.gov/study/NCT06239194)

KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
NCT ID: NCT05483491 (https://clinicaltrials.gov/study/NCT05483491)

Study of Aerobic Training for People Receiving Treatment for Breast Cancer
NCT ID: NCT05716893 (https://clinicaltrials.gov/study/NCT05716893)

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
NCT ID: NCT06590857 (https://clinicaltrials.gov/study/NCT06590857)

Tirzepatide Weight Loss for MRD+ Early Breast Cancer
NCT ID: NCT06517212 (https://clinicaltrials.gov/study/NCT06517212)

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
NCT ID: NCT05837767 (https://clinicaltrials.gov/study/NCT05837767)

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT ID: NCT06172478 (https://clinicaltrials.gov/study/NCT06172478)

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT ID: NCT06293898 (https://clinicaltrials.gov/study/NCT06293898)

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
NCT ID: NCT03606967 (https://clinicaltrials.gov/study/NCT03606967)

Conformal Ablative Radiotherapy in Older Women (CARMEN) With Breast Cancer Undergoing Non-Operative Management
NCT ID: NCT07242118 (https://clinicaltrials.gov/study/NCT07242118)

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy
NCT ID: NCT06953882 (https://clinicaltrials.gov/study/NCT06953882)

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
NCT ID: NCT07492641 (https://clinicaltrials.gov/study/NCT07492641)

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
NCT ID: NCT07318805 (https://clinicaltrials.gov/study/NCT07318805)

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer
NCT ID: NCT07483307 (https://clinicaltrials.gov/study/NCT07483307)

Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
NCT ID: NCT04084730 (https://clinicaltrials.gov/study/NCT04084730)

Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
NCT ID: NCT06268665 (https://clinicaltrials.gov/study/NCT06268665)

A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT ID: NCT07229313 (https://clinicaltrials.gov/study/NCT07229313)

Personalized Second Chance Breast Conservation (PSCBC): A Prospective Phase II Clinical Study
NCT ID: NCT04371913 (https://clinicaltrials.gov/study/NCT04371913)

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT ID: NCT02830724 (https://clinicaltrials.gov/study/NCT02830724)

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
NCT ID: NCT06926920 (https://clinicaltrials.gov/study/NCT06926920)

A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
NCT ID: NCT03671044 (https://clinicaltrials.gov/study/NCT03671044)

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
NCT ID: NCT05989828 (https://clinicaltrials.gov/study/NCT05989828)

ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
NCT ID: NCT06998407 (https://clinicaltrials.gov/study/NCT06998407)

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
NCT ID: NCT06075953 (https://clinicaltrials.gov/study/NCT06075953)

A Study of MGC026 in Participants With Advanced Solid Tumors
NCT ID: NCT06242470 (https://clinicaltrials.gov/study/NCT06242470)

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy
NCT ID: NCT05245812 (https://clinicaltrials.gov/study/NCT05245812)

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
NCT ID: NCT07701941 (https://clinicaltrials.gov/study/NCT07701941)

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
NCT ID: NCT06072612 (https://clinicaltrials.gov/study/NCT06072612)

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
NCT ID: NCT06582017 (https://clinicaltrials.gov/study/NCT06582017)

A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
NCT ID: NCT07524855 (https://clinicaltrials.gov/study/NCT07524855)

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
NCT ID: NCT07749586 (https://clinicaltrials.gov/study/NCT07749586)

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT ID: NCT06312176 (https://clinicaltrials.gov/study/NCT06312176)

Enhanced Pain Coping in Cancer (EPIC): A Study of Managing Treatment-Related Joint Pain in Breast Cancer Survivors
NCT ID: NCT06728579 (https://clinicaltrials.gov/study/NCT06728579)

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
NCT ID: NCT04434040 (https://clinicaltrials.gov/study/NCT04434040)

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT ID: NCT05633654 (https://clinicaltrials.gov/study/NCT05633654)

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
NCT ID: NCT07198724 (https://clinicaltrials.gov/study/NCT07198724)

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
NCT ID: NCT07578571 (https://clinicaltrials.gov/study/NCT07578571)

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
NCT ID: NCT06682793 (https://clinicaltrials.gov/study/NCT06682793)

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
NCT ID: NCT06318897 (https://clinicaltrials.gov/study/NCT06318897)

Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer
NCT ID: NCT07220135 (https://clinicaltrials.gov/study/NCT07220135)

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
NCT ID: NCT05123482 (https://clinicaltrials.gov/study/NCT05123482)

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
NCT ID: NCT04899908 (https://clinicaltrials.gov/study/NCT04899908)

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
NCT ID: NCT06026657 (https://clinicaltrials.gov/study/NCT06026657)

Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
NCT ID: NCT04458532 (https://clinicaltrials.gov/study/NCT04458532)

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT ID: NCT05894239 (https://clinicaltrials.gov/study/NCT05894239)

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
NCT ID: NCT05768932 (https://clinicaltrials.gov/study/NCT05768932)

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT ID: NCT01174121 (https://clinicaltrials.gov/study/NCT01174121)

Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast
NCT ID: NCT06129747 (https://clinicaltrials.gov/study/NCT06129747)

HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)
NCT ID: NCT07441889 (https://clinicaltrials.gov/study/NCT07441889)

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
NCT ID: NCT06409390 (https://clinicaltrials.gov/study/NCT06409390)

Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response
NCT ID: NCT03096418 (https://clinicaltrials.gov/study/NCT03096418)

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT ID: NCT06790693 (https://clinicaltrials.gov/study/NCT06790693)

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
NCT ID: NCT04852887 (https://clinicaltrials.gov/study/NCT04852887)

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
NCT ID: NCT05941507 (https://clinicaltrials.gov/study/NCT05941507)

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
NCT ID: NCT05770531 (https://clinicaltrials.gov/study/NCT05770531)

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
NCT ID: NCT06764940 (https://clinicaltrials.gov/study/NCT06764940)

Sacituzumab Govitecan In TNBC
NCT ID: NCT04230109 (https://clinicaltrials.gov/study/NCT04230109)

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT ID: NCT06982521 (https://clinicaltrials.gov/study/NCT06982521)

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NCT ID: NCT06586957 (https://clinicaltrials.gov/study/NCT06586957)

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
NCT ID: NCT03412877 (https://clinicaltrials.gov/study/NCT03412877)

Window Study of Intratumoral Mitazalimab in Breast Cancer (WINIT-BC)
NCT ID: NCT07319195 (https://clinicaltrials.gov/study/NCT07319195)

Brodalumab in the Treatment of Immune-Related Adverse Events
NCT ID: NCT06673329 (https://clinicaltrials.gov/study/NCT06673329)

Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD
NCT ID: NCT07694986 (https://clinicaltrials.gov/study/NCT07694986)

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT ID: NCT05768139 (https://clinicaltrials.gov/study/NCT05768139)

ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer
NCT ID: NCT04523857 (https://clinicaltrials.gov/study/NCT04523857)

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
NCT ID: NCT07011654 (https://clinicaltrials.gov/study/NCT07011654)

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
NCT ID: NCT04553770 (https://clinicaltrials.gov/study/NCT04553770)

Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Survivors
NCT ID: NCT07120100 (https://clinicaltrials.gov/study/NCT07120100)

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT ID: NCT05812807 (https://clinicaltrials.gov/study/NCT05812807)

A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer
NCT ID: NCT07905001 (https://clinicaltrials.gov/study/NCT07905001)

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
NCT ID: NCT07427394 (https://clinicaltrials.gov/study/NCT07427394)

A Study of DB-1310 in Advanced/Metastatic Solid Tumors
NCT ID: NCT05785741 (https://clinicaltrials.gov/study/NCT05785741)

HER-2 B Cell Peptide Vaccine
NCT ID: NCT06414733 (https://clinicaltrials.gov/study/NCT06414733)

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
NCT ID: NCT07054190 (https://clinicaltrials.gov/study/NCT07054190)

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
NCT ID: NCT03808337 (https://clinicaltrials.gov/study/NCT03808337)

Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)
NCT ID: NCT06103669 (https://clinicaltrials.gov/study/NCT06103669)

A Study of Revaree Plus in People With Breast Cancer
NCT ID: NCT07042581 (https://clinicaltrials.gov/study/NCT07042581)

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
NCT ID: NCT06545942 (https://clinicaltrials.gov/study/NCT06545942)

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
NCT ID: NCT05503797 (https://clinicaltrials.gov/study/NCT05503797)

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT ID: NCT06465069 (https://clinicaltrials.gov/study/NCT06465069)

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
NCT ID: NCT05902988 (https://clinicaltrials.gov/study/NCT05902988)

SMP-3124LP in Adults With Advanced Solid Tumors
NCT ID: NCT06526819 (https://clinicaltrials.gov/study/NCT06526819)

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
NCT ID: NCT07647328 (https://clinicaltrials.gov/study/NCT07647328)

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
NCT ID: NCT04771520 (https://clinicaltrials.gov/study/NCT04771520)

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
NCT ID: NCT04333706 (https://clinicaltrials.gov/study/NCT04333706)

Pulsed Electric Field Ablation for Metastatic Breast Cancer
NCT ID: NCT07487844 (https://clinicaltrials.gov/study/NCT07487844)

A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
NCT ID: NCT07095114 (https://clinicaltrials.gov/study/NCT07095114)

Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection
NCT ID: NCT07383649 (https://clinicaltrials.gov/study/NCT07383649)

Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients
NCT ID: NCT07460752 (https://clinicaltrials.gov/study/NCT07460752)

Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
NCT ID: NCT06974604 (https://clinicaltrials.gov/study/NCT06974604)

LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)
NCT ID: NCT04606030 (https://clinicaltrials.gov/study/NCT04606030)

Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
NCT ID: NCT05288777 (https://clinicaltrials.gov/study/NCT05288777)

BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer
NCT ID: NCT06085742 (https://clinicaltrials.gov/study/NCT06085742)

EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial
NCT ID: NCT06897488 (https://clinicaltrials.gov/study/NCT06897488)

X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
NCT ID: NCT04389281 (https://clinicaltrials.gov/study/NCT04389281)

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
NCT ID: NCT07341867 (https://clinicaltrials.gov/study/NCT07341867)

Cryoablation vs Lumpectomy in T1 Breast Cancers
NCT ID: NCT05505643 (https://clinicaltrials.gov/study/NCT05505643)

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
NCT ID: NCT07137416 (https://clinicaltrials.gov/study/NCT07137416)

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT ID: NCT05696626 (https://clinicaltrials.gov/study/NCT05696626)

Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients
NCT ID: NCT07071038 (https://clinicaltrials.gov/study/NCT07071038)

Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer
NCT ID: NCT06361940 (https://clinicaltrials.gov/study/NCT06361940)

A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes
NCT ID: NCT07748208 (https://clinicaltrials.gov/study/NCT07748208)

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT ID: NCT05269381 (https://clinicaltrials.gov/study/NCT05269381)

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT ID: NCT06695845 (https://clinicaltrials.gov/study/NCT06695845)

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
NCT ID: NCT07405801 (https://clinicaltrials.gov/study/NCT07405801)

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
NCT ID: NCT05898399 (https://clinicaltrials.gov/study/NCT05898399)

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer
NCT ID: NCT05504707 (https://clinicaltrials.gov/study/NCT05504707)

Evaluation and Outcomes of SAVI Scout MD for Localized Breast Surgery
NCT ID: NCT07686250 (https://clinicaltrials.gov/study/NCT07686250)

Definitive Radiation Therapy for Inoperable Breast Cancer
NCT ID: NCT07122713 (https://clinicaltrials.gov/study/NCT07122713)

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT ID: NCT06997029 (https://clinicaltrials.gov/study/NCT06997029)

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
NCT ID: NCT07216105 (https://clinicaltrials.gov/study/NCT07216105)

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
NCT ID: NCT07064018 (https://clinicaltrials.gov/study/NCT07064018)

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT ID: NCT05467891 (https://clinicaltrials.gov/study/NCT05467891)

Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer
NCT ID: NCT07076485 (https://clinicaltrials.gov/study/NCT07076485)

Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer
NCT ID: NCT05417308 (https://clinicaltrials.gov/study/NCT05417308)

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
NCT ID: NCT05005403 (https://clinicaltrials.gov/study/NCT05005403)

A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement
NCT ID: NCT07220967 (https://clinicaltrials.gov/study/NCT07220967)

Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
NCT ID: NCT04722692 (https://clinicaltrials.gov/study/NCT04722692)

Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
NCT ID: NCT05693766 (https://clinicaltrials.gov/study/NCT05693766)

Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
NCT ID: NCT07652242 (https://clinicaltrials.gov/study/NCT07652242)

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
NCT ID: NCT04683679 (https://clinicaltrials.gov/study/NCT04683679)

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT ID: NCT07062965 (https://clinicaltrials.gov/study/NCT07062965)

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
NCT ID: NCT07604571 (https://clinicaltrials.gov/study/NCT07604571)

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
NCT ID: NCT05559164 (https://clinicaltrials.gov/study/NCT05559164)

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
NCT ID: NCT05573126 (https://clinicaltrials.gov/study/NCT05573126)

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
NCT ID: NCT06062498 (https://clinicaltrials.gov/study/NCT06062498)

A Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT ID: NCT06253871 (https://clinicaltrials.gov/study/NCT06253871)

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
NCT ID: NCT06515470 (https://clinicaltrials.gov/study/NCT06515470)

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
NCT ID: NCT06488378 (https://clinicaltrials.gov/study/NCT06488378)

A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NCT ID: NCT06774963 (https://clinicaltrials.gov/study/NCT06774963)

PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
NCT ID: NCT07069595 (https://clinicaltrials.gov/study/NCT07069595)

Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
NCT ID: NCT03796559 (https://clinicaltrials.gov/study/NCT03796559)

A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
NCT ID: NCT07541079 (https://clinicaltrials.gov/study/NCT07541079)

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT ID: NCT07085767 (https://clinicaltrials.gov/study/NCT07085767)

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
NCT ID: NCT04305834 (https://clinicaltrials.gov/study/NCT04305834)

Asciminib in HER2+ Breast Cancer Brain Metastases
NCT ID: NCT07136428 (https://clinicaltrials.gov/study/NCT07136428)

NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients
NCT ID: NCT06845319 (https://clinicaltrials.gov/study/NCT06845319)

ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
NCT ID: NCT06460298 (https://clinicaltrials.gov/study/NCT06460298)

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
NCT ID: NCT07214532 (https://clinicaltrials.gov/study/NCT07214532)

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT ID: NCT07174336 (https://clinicaltrials.gov/study/NCT07174336)

A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
NCT ID: NCT07743190 (https://clinicaltrials.gov/study/NCT07743190)

Cancer Pain Management Using a Web-based Intervention
NCT ID: NCT06085313 (https://clinicaltrials.gov/study/NCT06085313)

IKS014 in Advanced Solid Tumors That Express HER2
NCT ID: NCT05872295 (https://clinicaltrials.gov/study/NCT05872295)

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
NCT ID: NCT06875128 (https://clinicaltrials.gov/study/NCT06875128)

Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
NCT ID: NCT06731894 (https://clinicaltrials.gov/study/NCT06731894)

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
NCT ID: NCT07424547 (https://clinicaltrials.gov/study/NCT07424547)

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
NCT ID: NCT07189871 (https://clinicaltrials.gov/study/NCT07189871)

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT ID: NCT06760819 (https://clinicaltrials.gov/study/NCT06760819)

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT ID: NCT05150691 (https://clinicaltrials.gov/study/NCT05150691)

The RolE of Prolonged Nightly faSTing to Improve Sleep and cOgnition in bREast Cancer Survivors
NCT ID: NCT06938555 (https://clinicaltrials.gov/study/NCT06938555)

VS-6766+Abema+Fulv in Met HR+/HER- BC
NCT ID: NCT05608252 (https://clinicaltrials.gov/study/NCT05608252)

HER2 Vaccine for Locally Advanced Breast Cancer
NCT ID: NCT06949410 (https://clinicaltrials.gov/study/NCT06949410)

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
NCT ID: NCT05491226 (https://clinicaltrials.gov/study/NCT05491226)

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
NCT ID: NCT07109726 (https://clinicaltrials.gov/study/NCT07109726)

A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of the Dayspring Technology for Patients With Breast Cancer Related Lymphedema (BCRL) After Lymphatic Surgery
NCT ID: NCT04888975 (https://clinicaltrials.gov/study/NCT04888975)

TRUDI: TDXD+Durva in HER2+/Low IBC
NCT ID: NCT05795101 (https://clinicaltrials.gov/study/NCT05795101)

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT ID: NCT06952803 (https://clinicaltrials.gov/study/NCT06952803)

Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer
NCT ID: NCT07276880 (https://clinicaltrials.gov/study/NCT07276880)

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
NCT ID: NCT06347068 (https://clinicaltrials.gov/study/NCT06347068)

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT ID: NCT04585750 (https://clinicaltrials.gov/study/NCT04585750)

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
NCT ID: NCT04090567 (https://clinicaltrials.gov/study/NCT04090567)

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
NCT ID: NCT06908928 (https://clinicaltrials.gov/study/NCT06908928)

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT ID: NCT07060807 (https://clinicaltrials.gov/study/NCT07060807)

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT ID: NCT06103864 (https://clinicaltrials.gov/study/NCT06103864)

Combined Immunotherapies in Metastatic ER+ Breast Cancer
NCT ID: NCT04563507 (https://clinicaltrials.gov/study/NCT04563507)

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
NCT ID: NCT05919108 (https://clinicaltrials.gov/study/NCT05919108)

A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
NCT ID: NCT04521764 (https://clinicaltrials.gov/study/NCT04521764)

Intratumoral N17350 in Advanced Solid Tumors
NCT ID: NCT07339176 (https://clinicaltrials.gov/study/NCT07339176)

Two Versus One Week Breast Radiotherapy (RT)
NCT ID: NCT06960707 (https://clinicaltrials.gov/study/NCT06960707)

A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer
NCT ID: NCT07768436 (https://clinicaltrials.gov/study/NCT07768436)

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
NCT ID: NCT07287098 (https://clinicaltrials.gov/study/NCT07287098)

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT ID: NCT06324357 (https://clinicaltrials.gov/study/NCT06324357)

Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Tissue Nanomechanical Phenotype Evaluation
NCT ID: NCT05774678 (https://clinicaltrials.gov/study/NCT05774678)

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT ID: NCT06926868 (https://clinicaltrials.gov/study/NCT06926868)

Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
NCT ID: NCT05846789 (https://clinicaltrials.gov/study/NCT05846789)

Radiation After No Axillary Nodal Sampling
NCT ID: NCT07723209 (https://clinicaltrials.gov/study/NCT07723209)

Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
NCT ID: NCT04965064 (https://clinicaltrials.gov/study/NCT04965064)

IDOV-Immune for Advanced Solid Tumors
NCT ID: NCT06910657 (https://clinicaltrials.gov/study/NCT06910657)

First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
NCT ID: NCT05627960 (https://clinicaltrials.gov/study/NCT05627960)

PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
NCT ID: NCT07190469 (https://clinicaltrials.gov/study/NCT07190469)

Pre-Operative Window of ET to Inform RT Decisions (POWER II)
NCT ID: NCT06507618 (https://clinicaltrials.gov/study/NCT06507618)

Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies
NCT ID: NCT07166042 (https://clinicaltrials.gov/study/NCT07166042)

Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
NCT ID: NCT06042569 (https://clinicaltrials.gov/study/NCT06042569)

Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer
NCT ID: NCT07506876 (https://clinicaltrials.gov/study/NCT07506876)

Pioglitazone Therapy Targeting Fatigue in Breast Cancer
NCT ID: NCT05013255 (https://clinicaltrials.gov/study/NCT05013255)

Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.
NCT ID: NCT07227233 (https://clinicaltrials.gov/study/NCT07227233)

Preoperative Nicotine Cessation for Women With Breast Cancer Recommended for Reconstruction
NCT ID: NCT06461650 (https://clinicaltrials.gov/study/NCT06461650)

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
NCT ID: NCT07102381 (https://clinicaltrials.gov/study/NCT07102381)

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
NCT ID: NCT06876714 (https://clinicaltrials.gov/study/NCT06876714)

Trial of Trastuzumab Deruxtecan in Previously Treated HER2
NCT ID: NCT06750484 (https://clinicaltrials.gov/study/NCT06750484)

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT ID: NCT06966700 (https://clinicaltrials.gov/study/NCT06966700)

Study of AVZO-021 in Patients With Advanced Solid Tumors
NCT ID: NCT05867251 (https://clinicaltrials.gov/study/NCT05867251)

A Study of Tetrathiomolybdate (TM) Plus Capecitabine
NCT ID: NCT06134375 (https://clinicaltrials.gov/study/NCT06134375)

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT ID: NCT06330064 (https://clinicaltrials.gov/study/NCT06330064)

Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
NCT ID: NCT05523947 (https://clinicaltrials.gov/study/NCT05523947)

Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
NCT ID: NCT06169371 (https://clinicaltrials.gov/study/NCT06169371)

Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
NCT ID: NCT04677816 (https://clinicaltrials.gov/study/NCT04677816)

Breast Re-irradiation After Second Ipsilateral Lumpectomy
NCT ID: NCT06867484 (https://clinicaltrials.gov/study/NCT06867484)

5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
NCT ID: NCT06961955 (https://clinicaltrials.gov/study/NCT06961955)

A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors
NCT ID: NCT07767474 (https://clinicaltrials.gov/study/NCT07767474)

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
NCT ID: NCT03604315 (https://clinicaltrials.gov/study/NCT03604315)

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT ID: NCT06395519 (https://clinicaltrials.gov/study/NCT06395519)

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
NCT ID: NCT04802759 (https://clinicaltrials.gov/study/NCT04802759)

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
NCT ID: NCT06324240 (https://clinicaltrials.gov/study/NCT06324240)

Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT ID: NCT05464810 (https://clinicaltrials.gov/study/NCT05464810)

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
NCT ID: NCT07020117 (https://clinicaltrials.gov/study/NCT07020117)

BRain-AVOidant Proton Craniospinal Irradiation for Leptomeningeal Metastases From Solid Tumor Malignancies
NCT ID: NCT07789912 (https://clinicaltrials.gov/study/NCT07789912)

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
NCT ID: NCT07158164 (https://clinicaltrials.gov/study/NCT07158164)

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
NCT ID: NCT07517198 (https://clinicaltrials.gov/study/NCT07517198)

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT ID: NCT04119024 (https://clinicaltrials.gov/study/NCT04119024)

Saci Nivo Rela for TNBC
NCT ID: NCT06963905 (https://clinicaltrials.gov/study/NCT06963905)

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT ID: NCT07213791 (https://clinicaltrials.gov/study/NCT07213791)

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
NCT ID: NCT04787042 (https://clinicaltrials.gov/study/NCT04787042)

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
NCT ID: NCT05422794 (https://clinicaltrials.gov/study/NCT05422794)

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
NCT ID: NCT07205822 (https://clinicaltrials.gov/study/NCT07205822)

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
NCT ID: NCT07287995 (https://clinicaltrials.gov/study/NCT07287995)

Feasibility and Acceptibility of a Multi-site Trial of Time Restircted Eating During Chemotheraply for Breast Cancer.
NCT ID: NCT07387445 (https://clinicaltrials.gov/study/NCT07387445)

Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)
NCT ID: NCT07629206 (https://clinicaltrials.gov/study/NCT07629206)

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
NCT ID: NCT06999187 (https://clinicaltrials.gov/study/NCT06999187)

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
NCT ID: NCT07310420 (https://clinicaltrials.gov/study/NCT07310420)

A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
NCT ID: NCT04144023 (https://clinicaltrials.gov/study/NCT04144023)

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
NCT ID: NCT07261631 (https://clinicaltrials.gov/study/NCT07261631)

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
NCT ID: NCT03990896 (https://clinicaltrials.gov/study/NCT03990896)

ATEMPT 2.0: Adjuvant T-DM1 vs TH
NCT ID: NCT04893109 (https://clinicaltrials.gov/study/NCT04893109)

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
NCT ID: NCT04150042 (https://clinicaltrials.gov/study/NCT04150042)

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
NCT ID: NCT06856499 (https://clinicaltrials.gov/study/NCT06856499)

BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
NCT ID: NCT06441890 (https://clinicaltrials.gov/study/NCT06441890)

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
NCT ID: NCT05076760 (https://clinicaltrials.gov/study/NCT05076760)

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
NCT ID: NCT06827613 (https://clinicaltrials.gov/study/NCT06827613)

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT ID: NCT06393374 (https://clinicaltrials.gov/study/NCT06393374)

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT ID: NCT07115043 (https://clinicaltrials.gov/study/NCT07115043)

Elacestrant in Advanced Triple Positive Breast Cancer
NCT ID: NCT07612215 (https://clinicaltrials.gov/study/NCT07612215)

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
NCT ID: NCT05983432 (https://clinicaltrials.gov/study/NCT05983432)

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
NCT ID: NCT07524322 (https://clinicaltrials.gov/study/NCT07524322)

Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
NCT ID: NCT07192432 (https://clinicaltrials.gov/study/NCT07192432)

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
NCT ID: NCT05315700 (https://clinicaltrials.gov/study/NCT05315700)

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
NCT ID: NCT06058377 (https://clinicaltrials.gov/study/NCT06058377)

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
NCT ID: NCT05534438 (https://clinicaltrials.gov/study/NCT05534438)

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT ID: NCT06726148 (https://clinicaltrials.gov/study/NCT06726148)

Personalized Prone Immobilization for Accelerated Partial Breast Radiotherapy
NCT ID: NCT07711847 (https://clinicaltrials.gov/study/NCT07711847)

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
NCT ID: NCT07017673 (https://clinicaltrials.gov/study/NCT07017673)

GammaPod Dose Escalation Radiation for Early Stage Breast Cancer
NCT ID: NCT04234386 (https://clinicaltrials.gov/study/NCT04234386)

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT ID: NCT05877599 (https://clinicaltrials.gov/study/NCT05877599)

Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
NCT ID: NCT06635980 (https://clinicaltrials.gov/study/NCT06635980)

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT ID: NCT07112053 (https://clinicaltrials.gov/study/NCT07112053)

A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer
NCT ID: NCT05412225 (https://clinicaltrials.gov/study/NCT05412225)

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT ID: NCT05774951 (https://clinicaltrials.gov/study/NCT05774951)

Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
NCT ID: NCT02422641 (https://clinicaltrials.gov/study/NCT02422641)

Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
NCT ID: NCT07311993 (https://clinicaltrials.gov/study/NCT07311993)

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
NCT ID: NCT07100106 (https://clinicaltrials.gov/study/NCT07100106)

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
NCT ID: NCT03449238 (https://clinicaltrials.gov/study/NCT03449238)

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
NCT ID: NCT05216432 (https://clinicaltrials.gov/study/NCT05216432)

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
NCT ID: NCT06797635 (https://clinicaltrials.gov/study/NCT06797635)

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
NCT ID: NCT04890613 (https://clinicaltrials.gov/study/NCT04890613)

Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients
NCT ID: NCT05074290 (https://clinicaltrials.gov/study/NCT05074290)

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT ID: NCT06993844 (https://clinicaltrials.gov/study/NCT06993844)

Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
NCT ID: NCT05856773 (https://clinicaltrials.gov/study/NCT05856773)

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
NCT ID: NCT04503265 (https://clinicaltrials.gov/study/NCT04503265)

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT ID: NCT06562192 (https://clinicaltrials.gov/study/NCT06562192)

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
NCT ID: NCT05570253 (https://clinicaltrials.gov/study/NCT05570253)

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
NCT ID: NCT06638307 (https://clinicaltrials.gov/study/NCT06638307)

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
NCT ID: NCT06218303 (https://clinicaltrials.gov/study/NCT06218303)

T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd
NCT ID: NCT07683754 (https://clinicaltrials.gov/study/NCT07683754)

Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC
NCT ID: NCT05464082 (https://clinicaltrials.gov/study/NCT05464082)

HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
NCT ID: NCT07459673 (https://clinicaltrials.gov/study/NCT07459673)

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
NCT ID: NCT05741164 (https://clinicaltrials.gov/study/NCT05741164)

Estradiol Plus Olaparib for Breast Cancer (PHOEBE)
NCT ID: NCT05900895 (https://clinicaltrials.gov/study/NCT05900895)

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
NCT ID: NCT06440005 (https://clinicaltrials.gov/study/NCT06440005)

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
NCT ID: NCT06400472 (https://clinicaltrials.gov/study/NCT06400472)

Single FrAction Interstitial BreaSt BracHytherApy
NCT ID: NCT07654257 (https://clinicaltrials.gov/study/NCT07654257)

Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
NCT ID: NCT03769415 (https://clinicaltrials.gov/study/NCT03769415)

Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
NCT ID: NCT07257484 (https://clinicaltrials.gov/study/NCT07257484)

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
NCT ID: NCT05095207 (https://clinicaltrials.gov/study/NCT05095207)

Neurotization of the Nipple Areolar Complex to Restore Sensation for Patients With Breast Cancer Undergoing Nipple Sparing Mastectomy and Reconstruction
NCT ID: NCT06153836 (https://clinicaltrials.gov/study/NCT06153836)

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
NCT ID: NCT05985655 (https://clinicaltrials.gov/study/NCT05985655)

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
NCT ID: NCT04038619 (https://clinicaltrials.gov/study/NCT04038619)

A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
NCT ID: NCT06678269 (https://clinicaltrials.gov/study/NCT06678269)

ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy
NCT ID: NCT06185205 (https://clinicaltrials.gov/study/NCT06185205)

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
NCT ID: NCT06377852 (https://clinicaltrials.gov/study/NCT06377852)

PRE-ISPY Phase I/II Oncology Platform Program
NCT ID: NCT05868226 (https://clinicaltrials.gov/study/NCT05868226)

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT ID: NCT05208762 (https://clinicaltrials.gov/study/NCT05208762)

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
NCT ID: NCT02945579 (https://clinicaltrials.gov/study/NCT02945579)

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
NCT ID: NCT06084481 (https://clinicaltrials.gov/study/NCT06084481)

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
NCT ID: NCT05824975 (https://clinicaltrials.gov/study/NCT05824975)

Exercise to ReGain Stamina and Energy (The EXERGISE Study)
NCT ID: NCT05684367 (https://clinicaltrials.gov/study/NCT05684367)

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
NCT ID: NCT04529044 (https://clinicaltrials.gov/study/NCT04529044)

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
NCT ID: NCT06625775 (https://clinicaltrials.gov/study/NCT06625775)

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
NCT ID: NCT05490472 (https://clinicaltrials.gov/study/NCT05490472)

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT ID: NCT06841354 (https://clinicaltrials.gov/study/NCT06841354)

Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
NCT ID: NCT07407920 (https://clinicaltrials.gov/study/NCT07407920)

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
NCT ID: NCT07488676 (https://clinicaltrials.gov/study/NCT07488676)

Time Restricted Eating During Chemotherapy for Breast Cancer
NCT ID: NCT05259410 (https://clinicaltrials.gov/study/NCT05259410)

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
NCT ID: NCT01766297 (https://clinicaltrials.gov/study/NCT01766297)

Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer
NCT ID: NCT04997993 (https://clinicaltrials.gov/study/NCT04997993)

Converting HR+ Breast Cancer Into an Individualized Vaccine
NCT ID: NCT03804944 (https://clinicaltrials.gov/study/NCT03804944)

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
NCT ID: NCT05029999 (https://clinicaltrials.gov/study/NCT05029999)

A Study of the TheraBionic P1 Device in Breast Cancer
NCT ID: NCT07218432 (https://clinicaltrials.gov/study/NCT07218432)

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
NCT ID: NCT06270706 (https://clinicaltrials.gov/study/NCT06270706)

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
NCT ID: NCT07182149 (https://clinicaltrials.gov/study/NCT07182149)

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
NCT ID: NCT06778863 (https://clinicaltrials.gov/study/NCT06778863)

Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
NCT ID: NCT07140172 (https://clinicaltrials.gov/study/NCT07140172)

Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
NCT ID: NCT07807345 (https://clinicaltrials.gov/study/NCT07807345)

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
NCT ID: NCT06435429 (https://clinicaltrials.gov/study/NCT06435429)

The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema
NCT ID: NCT05890677 (https://clinicaltrials.gov/study/NCT05890677)

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
NCT ID: NCT06176261 (https://clinicaltrials.gov/study/NCT06176261)

A Study of PHST001 in Advanced Solid Tumors
NCT ID: NCT06840886 (https://clinicaltrials.gov/study/NCT06840886)

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
NCT ID: NCT05305924 (https://clinicaltrials.gov/study/NCT05305924)

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
NCT ID: NCT06179303 (https://clinicaltrials.gov/study/NCT06179303)

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
NCT ID: NCT06956690 (https://clinicaltrials.gov/study/NCT06956690)

A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer
NCT ID: NCT06246968 (https://clinicaltrials.gov/study/NCT06246968)

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
NCT ID: NCT06533826 (https://clinicaltrials.gov/study/NCT06533826)

Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions
NCT ID: NCT06903468 (https://clinicaltrials.gov/study/NCT06903468)

Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction
NCT ID: NCT05190978 (https://clinicaltrials.gov/study/NCT05190978)

Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System
NCT ID: NCT05291507 (https://clinicaltrials.gov/study/NCT05291507)

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT ID: NCT06757634 (https://clinicaltrials.gov/study/NCT06757634)

Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy
NCT ID: NCT07137871 (https://clinicaltrials.gov/study/NCT07137871)

Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors
NCT ID: NCT05595499 (https://clinicaltrials.gov/study/NCT05595499)

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
NCT ID: NCT05098210 (https://clinicaltrials.gov/study/NCT05098210)

Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
NCT ID: NCT07660055 (https://clinicaltrials.gov/study/NCT07660055)

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
NCT ID: NCT06492759 (https://clinicaltrials.gov/study/NCT06492759)

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
NCT ID: NCT07007559 (https://clinicaltrials.gov/study/NCT07007559)

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
NCT ID: NCT06545682 (https://clinicaltrials.gov/study/NCT06545682)

Definitive Radiation for High-Risk Spine Metastases
NCT ID: NCT06165419 (https://clinicaltrials.gov/study/NCT06165419)

Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
NCT ID: NCT03463954 (https://clinicaltrials.gov/study/NCT03463954)

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
NCT ID: NCT06657222 (https://clinicaltrials.gov/study/NCT06657222)

Axelopran for Advanced Cancer in Patients Receiving Opioids
NCT ID: NCT07354919 (https://clinicaltrials.gov/study/NCT07354919)

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT ID: NCT05929768 (https://clinicaltrials.gov/study/NCT05929768)

Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
NCT ID: NCT03936478 (https://clinicaltrials.gov/study/NCT03936478)

Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
NCT ID: NCT05528133 (https://clinicaltrials.gov/study/NCT05528133)

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
NCT ID: NCT04468061 (https://clinicaltrials.gov/study/NCT04468061)

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT ID: NCT03424005 (https://clinicaltrials.gov/study/NCT03424005)

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
NCT ID: NCT06369285 (https://clinicaltrials.gov/study/NCT06369285)

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
NCT ID: NCT06756932 (https://clinicaltrials.gov/study/NCT06756932)

Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer
NCT ID: NCT05746325 (https://clinicaltrials.gov/study/NCT05746325)

Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
NCT ID: NCT03011684 (https://clinicaltrials.gov/study/NCT03011684)

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
NCT ID: NCT07145255 (https://clinicaltrials.gov/study/NCT07145255)

Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)
NCT ID: NCT06806930 (https://clinicaltrials.gov/study/NCT06806930)

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT ID: NCT07413939 (https://clinicaltrials.gov/study/NCT07413939)

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
NCT ID: NCT07285044 (https://clinicaltrials.gov/study/NCT07285044)

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
NCT ID: NCT06249048 (https://clinicaltrials.gov/study/NCT06249048)

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
NCT ID: NCT06263543 (https://clinicaltrials.gov/study/NCT06263543)

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
NCT ID: NCT05969860 (https://clinicaltrials.gov/study/NCT05969860)

Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
NCT ID: NCT03909282 (https://clinicaltrials.gov/study/NCT03909282)

A Study Evaluating the Feasibility and Compliance of Manual Lymphatic Drainage Comparing Indocyanine-Green (ICG) Guided vs. Traditional Guided in Patients Undergoing Axillary Node Dissection for the Treatment of Breast Cancer
NCT ID: NCT06327490 (https://clinicaltrials.gov/study/NCT06327490)

Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
NCT ID: NCT06518837 (https://clinicaltrials.gov/study/NCT06518837)

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT ID: NCT06380751 (https://clinicaltrials.gov/study/NCT06380751)

Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
NCT ID: NCT06902311 (https://clinicaltrials.gov/study/NCT06902311)

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
NCT ID: NCT05748834 (https://clinicaltrials.gov/study/NCT05748834)

Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy
NCT ID: NCT05472792 (https://clinicaltrials.gov/study/NCT05472792)

BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
NCT ID: NCT05977036 (https://clinicaltrials.gov/study/NCT05977036)

BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
NCT ID: NCT04891068 (https://clinicaltrials.gov/study/NCT04891068)

A Study of LY4175408 in Participants With Advanced Cancer
NCT ID: NCT07046923 (https://clinicaltrials.gov/study/NCT07046923)

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
NCT ID: NCT05377996 (https://clinicaltrials.gov/study/NCT05377996)

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
NCT ID: NCT05304962 (https://clinicaltrials.gov/study/NCT05304962)

A Study of Skipping Radiation Therapy in People With Breast Cancer
NCT ID: NCT07895511 (https://clinicaltrials.gov/study/NCT07895511)

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
NCT ID: NCT04641247 (https://clinicaltrials.gov/study/NCT04641247)

STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)
NCT ID: NCT05716516 (https://clinicaltrials.gov/study/NCT05716516)

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
NCT ID: NCT06139107 (https://clinicaltrials.gov/study/NCT06139107)

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
NCT ID: NCT06130826 (https://clinicaltrials.gov/study/NCT06130826)

A Study of Surgery and Radiotherapy in People With Breast Cancer
NCT ID: NCT07053085 (https://clinicaltrials.gov/study/NCT07053085)

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
NCT ID: NCT07287917 (https://clinicaltrials.gov/study/NCT07287917)

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
NCT ID: NCT05372640 (https://clinicaltrials.gov/study/NCT05372640)

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
NCT ID: NCT06439693 (https://clinicaltrials.gov/study/NCT06439693)

CBD for Breast Cancer Primary Tumors
NCT ID: NCT06148038 (https://clinicaltrials.gov/study/NCT06148038)

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
NCT ID: NCT04886531 (https://clinicaltrials.gov/study/NCT04886531)

CAN1012 in Pre-Malignant DCIS and LCIS
NCT ID: NCT07408856 (https://clinicaltrials.gov/study/NCT07408856)

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
NCT ID: NCT07222267 (https://clinicaltrials.gov/study/NCT07222267)

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
NCT ID: NCT06827236 (https://clinicaltrials.gov/study/NCT06827236)

Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
NCT ID: NCT06518057 (https://clinicaltrials.gov/study/NCT06518057)

Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
NCT ID: NCT04020575 (https://clinicaltrials.gov/study/NCT04020575)

A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT ID: NCT07114601 (https://clinicaltrials.gov/study/NCT07114601)

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
NCT ID: NCT05000294 (https://clinicaltrials.gov/study/NCT05000294)

A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
NCT ID: NCT04872166 (https://clinicaltrials.gov/study/NCT04872166)

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
NCT ID: NCT06099769 (https://clinicaltrials.gov/study/NCT06099769)

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
NCT ID: NCT07391774 (https://clinicaltrials.gov/study/NCT07391774)

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT ID: NCT04300556 (https://clinicaltrials.gov/study/NCT04300556)

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
NCT ID: NCT06580002 (https://clinicaltrials.gov/study/NCT06580002)

Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
NCT ID: NCT06435351 (https://clinicaltrials.gov/study/NCT06435351)

PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
NCT ID: NCT06896162 (https://clinicaltrials.gov/study/NCT06896162)

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
NCT ID: NCT05660083 (https://clinicaltrials.gov/study/NCT05660083)

Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer
NCT ID: NCT06525766 (https://clinicaltrials.gov/study/NCT06525766)

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
NCT ID: NCT05735080 (https://clinicaltrials.gov/study/NCT05735080)

Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery
NCT ID: NCT06450873 (https://clinicaltrials.gov/study/NCT06450873)

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
NCT ID: NCT05683418 (https://clinicaltrials.gov/study/NCT05683418)

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
NCT ID: NCT06500481 (https://clinicaltrials.gov/study/NCT06500481)

A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer
NCT ID: NCT07227831 (https://clinicaltrials.gov/study/NCT07227831)

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
NCT ID: NCT05325632 (https://clinicaltrials.gov/study/NCT05325632)

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
NCT ID: NCT04329065 (https://clinicaltrials.gov/study/NCT04329065)

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
NCT ID: NCT05524584 (https://clinicaltrials.gov/study/NCT05524584)

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
NCT ID: NCT07368998 (https://clinicaltrials.gov/study/NCT07368998)

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
NCT ID: NCT05232916 (https://clinicaltrials.gov/study/NCT05232916)

Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
NCT ID: NCT05313191 (https://clinicaltrials.gov/study/NCT05313191)

A Study of Romosozumab in People With Breast Cancer and Osteoporosis
NCT ID: NCT07776613 (https://clinicaltrials.gov/study/NCT07776613)

A Study of NX-1607 in Adults With Advanced Malignancies
NCT ID: NCT05107674 (https://clinicaltrials.gov/study/NCT05107674)

Cognitive Rehabilitation Following Breast Cancer Treatment
NCT ID: NCT06545045 (https://clinicaltrials.gov/study/NCT06545045)

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT ID: NCT06120283 (https://clinicaltrials.gov/study/NCT06120283)

IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases
NCT ID: NCT06092892 (https://clinicaltrials.gov/study/NCT06092892)

Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
NCT ID: NCT07158021 (https://clinicaltrials.gov/study/NCT07158021)

Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies
NCT ID: NCT06252662 (https://clinicaltrials.gov/study/NCT06252662)

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
NCT ID: NCT02476786 (https://clinicaltrials.gov/study/NCT02476786)

Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer
NCT ID: NCT04990921 (https://clinicaltrials.gov/study/NCT04990921)

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
NCT ID: NCT07016399 (https://clinicaltrials.gov/study/NCT07016399)

Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer
NCT ID: NCT06105684 (https://clinicaltrials.gov/study/NCT06105684)

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
NCT ID: NCT03740256 (https://clinicaltrials.gov/study/NCT03740256)

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
NCT ID: NCT06022029 (https://clinicaltrials.gov/study/NCT06022029)

CONFIRM: Magnetic Resonance Guided Radiation Therapy
NCT ID: NCT04368702 (https://clinicaltrials.gov/study/NCT04368702)

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
NCT ID: NCT05092373 (https://clinicaltrials.gov/study/NCT05092373)

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
NCT ID: NCT04768426 (https://clinicaltrials.gov/study/NCT04768426)

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
NCT ID: NCT05283330 (https://clinicaltrials.gov/study/NCT05283330)

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
NCT ID: NCT04557449 (https://clinicaltrials.gov/study/NCT04557449)

TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
NCT ID: NCT06251544 (https://clinicaltrials.gov/study/NCT06251544)

A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer
NCT ID: NCT07401381 (https://clinicaltrials.gov/study/NCT07401381)

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
NCT ID: NCT06784193 (https://clinicaltrials.gov/study/NCT06784193)

Assessment of Topical Minoxidil on Intraoperative Flap Perfusion and Cutaneous Flap Viability in Breast Recon
NCT ID: NCT07264790 (https://clinicaltrials.gov/study/NCT07264790)

Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol
NCT ID: NCT07308717 (https://clinicaltrials.gov/study/NCT07308717)

Study of PF-07248144 in Advanced or Metastatic Solid Tumors
NCT ID: NCT04606446 (https://clinicaltrials.gov/study/NCT04606446)

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
NCT ID: NCT05417594 (https://clinicaltrials.gov/study/NCT05417594)

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
NCT ID: NCT07340541 (https://clinicaltrials.gov/study/NCT07340541)

Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
NCT ID: NCT06954831 (https://clinicaltrials.gov/study/NCT06954831)

Circulating Tumor DNA
NCT ID: NCT06923527 (https://clinicaltrials.gov/study/NCT06923527)

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT ID: NCT05646862 (https://clinicaltrials.gov/study/NCT05646862)

A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer or Malignant Peritoneal Mesothelioma
NCT ID: NCT06623396 (https://clinicaltrials.gov/study/NCT06623396)

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
NCT ID: NCT04222413 (https://clinicaltrials.gov/study/NCT04222413)

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
NCT ID: NCT07503808 (https://clinicaltrials.gov/study/NCT07503808)

Ultra-Hypofractionated vs. Hypofractionated Radiation for Node-Positive Breast Cancer
NCT ID: NCT06559540 (https://clinicaltrials.gov/study/NCT06559540)

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
NCT ID: NCT06245889 (https://clinicaltrials.gov/study/NCT06245889)

A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
NCT ID: NCT05187832 (https://clinicaltrials.gov/study/NCT05187832)

Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
NCT ID: NCT07203378 (https://clinicaltrials.gov/study/NCT07203378)

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
NCT ID: NCT06238921 (https://clinicaltrials.gov/study/NCT06238921)

The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer
NCT ID: NCT05780814 (https://clinicaltrials.gov/study/NCT05780814)

Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
NCT ID: NCT05592938 (https://clinicaltrials.gov/study/NCT05592938)

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
NCT ID: NCT07361562 (https://clinicaltrials.gov/study/NCT07361562)

Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer
NCT ID: NCT07402473 (https://clinicaltrials.gov/study/NCT07402473)

Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
NCT ID: NCT06072807 (https://clinicaltrials.gov/study/NCT06072807)

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT ID: NCT07173751 (https://clinicaltrials.gov/study/NCT07173751)

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
NCT ID: NCT01042379 (https://clinicaltrials.gov/study/NCT01042379)

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer and HR+/HER2- Metastatic Breast Cancer
NCT ID: NCT05318469 (https://clinicaltrials.gov/study/NCT05318469)

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.